MedTrace Logo

Trial of MK-2206 + Endocrine Treatment in Patients With Hormone Receptor Positive Breast Cancer

NCT01240941 · Status: WITHDRAWN · Phase: PHASE2 · Type: INTERVENTIONAL

Last updated 2013-08-20

No results posted yet for this study

Summary

This is a phase II Trial of MK-2206 in combination with Endocrine Therapy in patients with Hormone Receptor Breast Cancer. After the maximum tolerated dose is determined in the phase 1b trial (under a separate NCT number), efficacy will be evaluated among 17 patients.

Conditions

Interventions

DRUG

MK-2206

dose to be determined on the Phase 1b trial (listed under a separate NCT number)

DRUG

Exemestane

25 mg orally daily

DRUG

Goserelin

3.6 mg orally monthly

Sponsors & Collaborators

  • Vanderbilt-Ingram Cancer Center

    lead OTHER

Principal Investigators

  • Vandana Abramson, M.D. · Vanderbilt University

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2011-02-28
Primary Completion
2012-06-30
Completion
2012-12-31

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01240941 on ClinicalTrials.gov